PMVP: pmvpharma.com Net earnings per share for the last 12 months

Symbol and logo of brand PMV Pharmaceuticals, Inc. (PMVP)

PMV Pharmaceuticals is developing targeted oncology therapies for p53 protein regeneration, which promises colossal profits upon successful testing. This 12-month net income per share chart visualizes this trajectory, where -1.52 indicates the current level. PMV Pharmaceuticals monetizes unique patents through partnerships with pharma behemoths, and its R&D pipeline featuring the PC14586 molecule is currently undergoing intensive Phase II clinical trials.

PMVP (PMV Pharmaceuticals) Net earnings per share (EPS TTM) history from 07/04/2022 to 11/15/2026

Analytical breakdowns for PMV Pharmaceuticals

Basic company analysis:PMV Pharmaceuticals - PMVP
Manufactured products of PMV Pharmaceuticals Inc.

PMV Pharmaceuticals (PMVP) occupies a unique niche in oncology thanks to its proprietary p53 protein restoration technology. This metric measures the final profit attributable to a single common share per year, excluding the impact of capital dilution. An analysis of the net income per share TTM fundamental indicator allows for an assessment of the efficiency of monetizing the company's technological advantage. Growth in this indicator confirms the viability of the business model during the drug development period. Positive dynamics signal that PMV Pharmaceuticals (PMVP) is transitioning to a stage of real capitalization of its innovations.

Who PMV Pharmaceuticals competes with

GMAB: Net earnings per share for the last 12 months|Earnings per share for the trailing year EXEL (Exelixis Corp)|NUVL (Nuvalent) - Net earnings per share for the last 12 months|KYMR: Earnings per share for the last four quarters|IDYA (IDEAYA Corp) - Net earnings per share (EPS TTM)|Net earnings per share (EPS TTM) enliventherapeutics.com|Earnings per share for the last twelve months ORIC Pharmaceuticals, Inc. (ORIC)|RLAY (Relay Therapeutics, Inc.) - Earnings per share for the trailing year|Net earnings per share (EPS TTM) NRIX (Nurix Therapeutics Inc)|Net earnings per share for the trailing year Tyra Bio|Verastem Oncology - Net earnings per share (EPS TTM)|Net earnings per one share for the last twelve months Monte Rosa Therapeutics, Inc.|CGEM (Cullinan Therapeutics) - Net earnings per share for the last 12 months|IMRX: Earnings per share for the last four quarters|CCCC (c4therapeutics.com) - Net earnings per share (EPS TTM)|Net earnings per one share for the last twelve months Black Diamond Therapeutics Inc. BDTX|Net earnings per share (EPS TTM) RPTX|Karyopharm - Earnings per share for the last 12 months|Propanc Biopharma Inc - Net earnings per share for the last 12 months|Earnings per share for the trailing year BGMS|AADI: Net earnings per share for the last 12 months|aileronrx.com - Earnings per share for the last four quarters|BPMC: Net earnings per share (EPS TTM)|GlycoMimetics Inc. - Earnings per share for the trailing year|SWTX (SpringWorks Therapeutics, Inc) - Net earnings per share (EPS TTM)